BTIG Maintains Buy on Abivax, Raises Price Target to $175

Benzinga Newsdesk www.benzinga.com Positive 69.9%

Neg 0% Neu 0% Pos 69.9%

BTIG analyst Julian Harrison maintains Abivax (NASDAQ:ABVX) with a Buy and raises the price target from $150 to $175.

Comments

No comments yet. Be the first!